🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

676 results for “Solid” Clear

  1. Master Protocol of Sotorasib (AMG 510) in Subjects with Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)

    Amgen

    Advanced Solid Tumors Kirsten Rat Sarcoma (KRAS) pG12C Mutation

    phase 1 other active

    1 trial

  2. Midazolam

    Takeda

    Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors

    phase 1 small molecule completed

    1 trial

  3. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Advanced Malignant Solid Tumors

    phase 1 small molecule completed

    3 trials

  4. Neratinib 160 mg

    PUMA BIOTECHNOLOGY, INC.

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  5. Nimotuzumab

    Biotech Pharmaceutical Co.,

    Solid Tumors

    phase 1 small molecule active

    1 trial

  6. Niraparib

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  7. OKI-179

    OnKure Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  8. OKN4395

    Chongqing Precision Biotech Co., Ltd

    Solid Tumours

    phase 1 small molecule active

    1 trial

  9. OMP-18R5

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 mab completed

    1 trial

  10. OMP-21M18

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  11. OMP-305B83

    Mereo BioPharma Group plc

    Advanced Solid Tumor Malignancies

    phase 1 small molecule completed

    1 trial

  12. OMP-52M51

    Mereo BioPharma Group plc

    Relapsed or Refractory Solid Tumors

    phase 1 small molecule completed

    1 trial

  13. OMP-54F28

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 mab completed

    1 trial

  14. OMP-59R5

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  15. ONX-0801

    United Therapeutics Europe Ltd

    Solid Tumours

    phase 1 small molecule completed

    1 trial

  16. ORIC-101

    Topiloric/Uriadec

    Solid Tumor

    phase 1 small molecule terminated

    1 trial

  17. ORIC-114 Dose 1 + amivantamab

    Topiloric/Uriadec

    Solid Tumors

    phase 1 small molecule active

    1 trial

  18. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Solid Tumor

    phase 1 small molecule completed

    2 trials

  19. PET-imaging of two Vartumabs (F8scFv and C9scFv) in patients with solid tumors – a Phase 0 basket trial

    Lacuna Pharma Pty Ltd

    Multiple solid tumors including: colorectal carcinoma (CRC), pancreatic carcinoma, oesophageal or gastric carcinoma, head and neck squamous cell carcinoma (HNSCC), chondrosarcoma or osteosarcoma, bladder carcinoma, lung carcinoma and glioblastoma.

    phase 1 other active

    1 trial

  20. PLN-101095

    PLIANT THERAPEUTICS, INC.

    Advanced or Metastatic Solid Tumor

    phase 1 small molecule active

    1 trial

  21. PRT543

    Prelude Therapeutics Inc

    Relapsed/Refractory Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  22. PRT7732

    Prelude Therapeutics Inc

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  23. PRT811

    Prelude Therapeutics Inc

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  24. PYX-106

    Pyxis Oncology

    Solid Tumor

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources